With a renewed focus on bringing sustainable biopesticides and a coronavirus vaccine to market, GreenLight Biosciences, the rapidly growing agtech and life sciences firm based in Medford, has brought in a whopping $102 million in Series D funding. The round, which was oversubscribed, was led by Chinese investment firm Morningside Ventures. S2G Ventures, Coromorant Asset Management, Continental Grain Company, Fall…
Read More
There’s a long-standing assumption in the pharmaceutical industry that when drug molecules enter a cell, they spread through it evenly — but, says biologist Rick Young, “that could not be further from the truth”. In a study published today in Science1, Young and his colleagues at the Whitehead Institute in Cambridge, Massachusetts, show that cancer-drug compounds become concentrated in precise spots…
Read More
The Broad Institute has named Fei Chen as a core institute member. In this role, Chen will continue the scientific work he has undertaken as a Schmidt Fellow at the Broad since 2017, aimed at using microscopy and spatial genomics to learn about cells in their native habitat. He also joins the Department of Stem Cell and Regenerative Biology at Harvard University as an assistant professor.…
Read More
A diagnosis of glioblastoma, a fast-growing type of brain cancer, is devastating for patients and their families, as no cure is available and patients survive for only a median of 15 months. A team led by investigators at Massachusetts General Hospital (MGH) has now uncovered a mechanism used by glioblastoma cells to become aggressive and resistant to chemotherapy and radiation.…
Read More
In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model. An increase in megakaryocyte numbers is thought to be the cause of many problems observed in this disease. This type of treatment approach…
Read More
Imagine if scientists could stop the coronavirus infection in its tracks simply by diverting its attention away from living lung cells? A new therapeutic countermeasure, announced in a Nano Letters study by researchers from Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) and the University of California San Diego, appears to do just that in experiments that were carried out at the NEIDL in…
Read More
The microbiome is the trillions of microorganisms that live in and on the body. Increasingly, they are found to play a significant role in numerous diseases ranging from gastrointestinal disorders to amyotrophic lateral sclerosis (ALS) and other diseases. Researchers believe that by manipulating the microbiome, they may be able to treat those diseases. Finch Therapeutics reported positive topline results from PRISM3, its Phase II…
Read More
The discovery of how certain key structures in the kidneys are formed could have important implications for treating renal fibrosis (or scarring), a feature of chronic kidney disease (CKD), according to a new study by a researcher at Massachusetts General Hospital. Interestingly, the research that led to these findings, published in the journal Developmental Cell on June 17, 2020, arose from a previous…
Read More
A new method of screening thousands of drugs in freshly collected human tumor cells can help identify which of the drugs are most likely to be effective against those cancers, Dana-Farber Cancer Institute researchers report today in a study published in Science Signaling. Because the technique uses tumor cells that less than a day earlier were in patients’ bodies, it may well prove…
Read More
A company developing a drug to address the growing need for safe ways to condition patients receiving cell and gene therapies is partnering with a firm developing single letter-level gene editing to investigate ways to apply its approach in patients with blood disorders. Cambridge, Massachusetts-based Magenta Therapeutics and Beam Therapeutics said Monday that they had signed a non-exclusive research and collaboration agreement…
Read More